APIRx-1602 is under clinical development by Incannex Healthcare and currently in Phase II for Psoriasis. According to GlobalData, Phase II drugs for Psoriasis have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APIRx-1602’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APIRx-1602 (AX-1602) is under development for the treatment of psoriasis. It is applied topically as an ointment. The drug candidate comprises of cannabigerol (CBG) and Cannabidiol (CBD). The drug candidate acts by targeting CB1 and CB2 receptors.
It was also under development for the treatment of atopic dermatitis (eczema) and vitiligo.
Incannex Healthcare overview
Incannex Healthcare, is a pharmaceutical company. The company offers the development and manufacturing of cannabinoid medicine and therapeutic products. Its product portfolio includes releafia, nutralesic, inflammex, and cannagesia. Incannex Healthcare products are used in the treatment of obstructive sleep apnea, traumatic brain injury, sepsis-associated acute respiratory distress syndrome, and temporomandibular joint dysfunction. It also provides clinical trials and research and development services. It operates in Australia and New Zealand. Incannex Healthcare is headquartered in Melbourne, Victoria, Australia.
For a complete picture of APIRx-1602’s drug-specific PTSR and LoA scores, buy the report here.